Clinical trials: CMV
CMV
Detection of Cytomegalovirus Virus in Neonates
To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
- Trial name
- CMV (NCT03251261)
- Testing
- illumigene CMV assay, illumipro-10
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 1,615 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Hematologic Malignancy
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
- Trial name
- NCT07511127
- Testing
- Maribavir
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Ruijin Hospital
Neoplasms
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
According to a survey from Department of Health in 2004, cancer has been the leading cause of death in the Taiwan area. In 2004, people died of cancer, accounting for 27.2 percent of all deaths.
- Trial name
- NCT00521287
- Testing
- Immune profiling and DC vaccine
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Cytomegalovirus (CMV) Infection, Kidney Transplant Recipient
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in…
- Trial name
- RESPECT-CMV (NCT07488481)
- Testing
- SYN002
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Adenovirus Infection, EBV
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell…
- Conditions
- Adenovirus Infection, EBV, Cytomegalovirus Infections, Cytokine Capture System
- Trial name
- CCS (NCT02007356)
- Testing
- IFN-γ positive selected T-cells
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Cytomegalovirus Retinitis, HIV Infections
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis.
- Trial name
- NCT00002377
- Testing
- Valganciclovir, Ganciclovir
- Where
- 19 sites in United States, Canada
- Sponsor
- Hoffmann-La Roche
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who…
- Trial name
- NCT03354728
- Testing
- Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- City of Hope Medical Center
Allogeneic Stem Cell Transplantation
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease
The purpose of this study is to determine the safety and feasibility of CMV specific, T cell adoptive immunotherapy in patients who have undergone allogeneic stem cell transplantation for malignant disease.
- Trial name
- CMV-BMT (NCT00611637)
- Testing
- CMV pp65 Specific T Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Kim Lyerly
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cytomegalovirus Infections
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
- Trial name
- NCT04478474
- Testing
- Ganciclovir
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York Medical College
Cytomegalovirus Infections
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Many risk factors are known to be associated with high risk of developing CMV infection in positive CMV-serostatus patients: negative CMV-serostatus donor, unrelated or mismatched donor, use of antithymocyte globulin (ATG), and…
- Trial name
- CMV-GVHD (NCT05370976)
- Testing
- Cytotect®CP
- Where
- France
- Volunteers
- 2 people
- Sponsor
- University Hospital, Lille
Infectious Complications Following HSCT
Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT
DESIGN: Disease registry - non-interventional. INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.
- Trial name
- EPROS (NCT02873325)
- Testing
- antiviral therapies for CMV and/or ADV
- Where
- 2 sites in United Kingdom
- Volunteers
- 1 people
- Sponsor
- Cell Medica Ltd
Cytomegalovirus Retinitis, Acute Renal Failure
Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
Cidofovir is an acyclic nucleotide analog with broad-spectrum antiviral activity against herpesviruses. Its potency in inhibiting HCMV has been shown in conventional in vitro studies.
- Trial name
- NCT01866397
- Testing
- Cidofovir pharmacokinetics
- Where
- Austria
- Volunteers
- 1 people
- Sponsor
- Medical University of Vienna
Glioblastoma Multiforme, Glioblastoma
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV
- Trial name
- ATTAC-II (NCT02465268)
- Testing
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of Florida
CMV, Lung Transplant Recipient
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant…
- Trial name
- CLEAR-CMV (NCT07235683)
- Testing
- Letermovir, Valganciclovir/Ganciclovir
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Infection
Study of Prophylactic Vs Preemptive Valganciclovir
This is a study of prophylactic Vs preemptive oral valganciclovir for management of cytomegalovirus infection in adult renal transplant recipients looking at clinical and pharmacoeconomic outcomes
- Trial name
- NCT00374686
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Cytomegalovirus Retinitis, HIV Infections
Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
To compare cidofovir with a commonly used treatment regimen, ganciclovir given by mouth (oral) and through an eye device (intraocular) , in order to determine the safety and effectiveness of cidofovir in preventing vision loss in…
- Trial name
- NCT00000894
- Testing
- Cidofovir, Probenecid, Ganciclovir
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Congenital CMV Infection
Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit
Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of pediatric hearing loss and an important cause of neurodevelopmental delay.
- Trial name
- NCT02680743
- Testing
- Education of parents to pursue prompt hearing screening.
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Nebraska
Cytomegalovirus Infections
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection
OBJECTIVES: I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates with symptomatic congenital cytomegalovirus infection with central nervous system disease.
- Trial name
- NCT00004278
- Testing
- ganciclovir
- Volunteers
- 130 people
- Sponsor
- National Center for Research Resources (NCRR)